Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

New research contradicts previous reports on blood-thinner clopidogrel

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

30 Aug 2010

New campaign to create awareness on atrial fibrillation related strokes

Mission 1 Million Getting to the Heart of Stroke launches today announcing a worldwide effort to help prevent as many as 1 million atrial fibrillation (AF) related strokes through increased awareness and understanding.

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

GWAS finds new genetic link between Parkinson's disease and inflammation

A hunt throughout the human genome for variants associated with common, late-onset Parkinson's disease has revealed a new genetic link that implicates the immune system and offers new targets for drug development.

30 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

World's tallest man undergoes Gamma Knife surgery

Much of Sultan Kosen's eight feet, two-inch stature rose up in an 17-year period starting at age 10, when the benign tumor in his brain's pituitary gland highjacked the organ, causing it to secrete massive amounts of growth hormone, making Mr. Kosen's body grow fast and grow without ceasing. He will need to wait several months to find out if his Gamma Knife® surgery last Thursday at the University of Virginia (UVA, Charlottesville, Va.) has inactivated the tumor and he has reached his final height, but his physicians are optimistic.

27 Aug 2010

Athera Biotechnologies, Electra-Box Diagnostica sign distribution agreement for 'CVDefine' kit

Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.

27 Aug 2010

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.

27 Aug 2010

Researchers find two high-fat diets reduce absence epilepsy in children

Two high-fat diets the classic ketogenic and a modified version of the Atkins can reduce and, in some cases, completely eliminate seizures in children with a common seizure disorder known as absence epilepsy, say researchers from Johns Hopkins Children's Center.

27 Aug 2010

New vibration technology to reduce stubborn stomach fat

For millions of dieters it seems impossible to lose belly fat no matter however carefully they watch what they eat or how many sit-ups they do. Some people give up and blame it on genetics, metabolism or body type and simply accept it as a fact of life. For whatever the reason, many Americans discover that stubborn fat around the stomach and love handles will not melt away despite their best efforts. Now a fitness research company says there is an effective way to win the battle of the bulge without special diets, drinks or difficult exercises.

27 Aug 2010

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Developing specific liver cell lines from stem cells holds promise for new liver disease treatment: Researchers

By creating diseased liver cells from a small sample of human skin, scientists have for the first time shown that stem cells can be used to model a diverse range of inherited disorders. The University of Cambridge researchers' findings, which will hopefully lead to new treatments for those suffering from liver diseases, were published today in The Journal of Clinical Investigation.

26 Aug 2010

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

An international study led by biologists and neuroscientists from the University of Pennsylvania has identified a new genetic risk factor for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels.

25 Aug 2010

Migraine with aura increases risk of heart disease: Research

Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke.

25 Aug 2010

Stroke News and Research

Further Reading

New research contradicts previous reports on blood-thinner clopidogrel

New campaign to create awareness on atrial fibrillation related strokes

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

GWAS finds new genetic link between Parkinson's disease and inflammation

FDA approves Novartis' Tekamlo for treatment of high blood pressure

World's tallest man undergoes Gamma Knife surgery

Athera Biotechnologies, Electra-Box Diagnostica sign distribution agreement for 'CVDefine' kit

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

Researchers find two high-fat diets reduce absence epilepsy in children

New vibration technology to reduce stubborn stomach fat

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Developing specific liver cell lines from stem cells holds promise for new liver disease treatment: Researchers

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

Migraine with aura increases risk of heart disease: Research

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News